| 1 |
20156671 | Targeted cytotoxic somatostatin analog AN-162 inhibits growth of human colon carcinomas and increases sensitivity of doxorubicin resistant murine leukemia cells. | 2010 Aug 1 |
2 |
| 2 |
20359855 | The mechanisms of somatostatin induced enhanced chemosensitivity of gallbladder cancer cell line to doxorubicin: cell cycle modulation plus target enzyme up-regulation. | 2010 Sep |
9 |
| 3 |
21162905 | [Somatostatin enhanced anti-tumor effect of doxorubicin on gallbladder cancer cells through the regulation of intracellular drug concentration]. | 2010 Oct 19 |
10 |
| 4 |
25961976 | The use of peptide analogs for the treatment of gastrointestinal, pancreatic, liver and urinary bladder cancers. | 2010 Jan 1 |
1 |
| 5 |
19491659 | Preclinical evaluation of properties of a new targeted cytotoxic somatostatin analog, AN-162 (AEZS-124), and its effects on tumor growth inhibition. | 2009 Aug |
3 |
| 6 |
16047355 | Targeted therapy with a cytotoxic somatostatin analog, AN-238, inhibits growth of human experimental endometrial carcinomas expressing multidrug resistance protein MDR-1. | 2005 Sep 15 |
6 |
| 7 |
11290438 | A targeted cytotoxic somatostatin (SST) analogue, AN-238, inhibits the growth of H-69 small-cell lung carcinoma (SCLC) and H-157 non-SCLC in nude mice. | 2001 Mar |
3 |
| 8 |
10690557 | Regression of U-87 MG human glioblastomas in nude mice after treatment with a cytotoxic somatostatin analog AN-238. | 2000 Feb |
4 |
| 9 |
9465096 | Synthesis and biological evaluation of cytotoxic analogs of somatostatin containing doxorubicin or its intensely potent derivative, 2-pyrrolinodoxorubicin. | 1998 Feb 17 |
1 |